Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
PETS's Cash-to-Debt is ranked higher than
99% of the 338 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.50 vs. PETS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
PETS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.92
PETS's Equity-to-Asset is ranked higher than
98% of the 339 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.42 vs. PETS: 0.92 )
Ranked among companies with meaningful Equity-to-Asset only.
PETS' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.13  Med: 0.87 Max: 0.95
Current: 0.92
-0.13
0.95
Interest Coverage No Debt
PETS's Interest Coverage is ranked higher than
99% of the 396 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.23 vs. PETS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PETS' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: 35.59
Beneish M-Score: -1.69
WACC vs ROIC
4.89%
58.72%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 14.23
PETS's Operating Margin % is ranked higher than
96% of the 339 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.94 vs. PETS: 14.23 )
Ranked among companies with meaningful Operating Margin % only.
PETS' s Operating Margin % Range Over the Past 10 Years
Min: 10.92  Med: 13.53 Max: 17.02
Current: 14.23
10.92
17.02
Net Margin % 9.00
PETS's Net Margin % is ranked higher than
95% of the 340 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.78 vs. PETS: 9.00 )
Ranked among companies with meaningful Net Margin % only.
PETS' s Net Margin % Range Over the Past 10 Years
Min: 6.99  Med: 8.83 Max: 10.91
Current: 9
6.99
10.91
ROE % 25.40
PETS's ROE % is ranked higher than
91% of the 332 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 8.74 vs. PETS: 25.40 )
Ranked among companies with meaningful ROE % only.
PETS' s ROE % Range Over the Past 10 Years
Min: 18.7  Med: 26.36 Max: 33.12
Current: 25.4
18.7
33.12
ROA % 22.98
PETS's ROA % is ranked higher than
99% of the 342 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.31 vs. PETS: 22.98 )
Ranked among companies with meaningful ROA % only.
PETS' s ROA % Range Over the Past 10 Years
Min: 16.88  Med: 23.74 Max: 29.73
Current: 22.98
16.88
29.73
ROC (Joel Greenblatt) % 97.13
PETS's ROC (Joel Greenblatt) % is ranked higher than
97% of the 341 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.43 vs. PETS: 97.13 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PETS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 91.28  Med: 114.3 Max: 194.27
Current: 97.13
91.28
194.27
3-Year Revenue Growth Rate 0.60
PETS's 3-Year Revenue Growth Rate is ranked lower than
72% of the 313 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.10 vs. PETS: 0.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PETS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -0.3  Med: 12.9 Max: 58
Current: 0.6
-0.3
58
3-Year EBITDA Growth Rate 5.30
PETS's 3-Year EBITDA Growth Rate is ranked lower than
52% of the 281 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.20 vs. PETS: 5.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PETS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -8.7  Med: 16.7 Max: 106.3
Current: 5.3
-8.7
106.3
3-Year EPS without NRI Growth Rate 5.90
PETS's 3-Year EPS without NRI Growth Rate is ranked higher than
52% of the 249 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.20 vs. PETS: 5.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PETS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -9  Med: 14.9 Max: 104.1
Current: 5.9
-9
104.1
GuruFocus has detected 1 Warning Sign with PetMed Express Inc $PETS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PETS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

PETS Guru Trades in Q1 2016

Joel Greenblatt 15,396 sh (New)
Chuck Royce 401,500 sh (+33.17%)
Ken Fisher 187,116 sh (unchged)
John Buckingham 142,406 sh (-2.13%)
Jim Simons 1,614,500 sh (-5.27%)
Barrow, Hanley, Mewhinney & Strauss 26,526 sh (-82.83%)
» More
Q2 2016

PETS Guru Trades in Q2 2016

Paul Tudor Jones 18,400 sh (New)
Jim Simons 1,662,315 sh (+2.96%)
Chuck Royce 401,500 sh (unchged)
Barrow, Hanley, Mewhinney & Strauss Sold Out
Joel Greenblatt Sold Out
Ken Fisher 148,049 sh (-20.88%)
John Buckingham 102,012 sh (-28.37%)
» More
Q3 2016

PETS Guru Trades in Q3 2016

Chuck Royce 401,500 sh (unchged)
Paul Tudor Jones Sold Out
John Buckingham 100,190 sh (-1.79%)
Jim Simons 1,567,915 sh (-5.68%)
Ken Fisher 115,453 sh (-22.02%)
» More
Q4 2016

PETS Guru Trades in Q4 2016

Jim Simons 1,597,700 sh (+1.90%)
John Buckingham 96,699 sh (-3.48%)
Chuck Royce 309,600 sh (-22.89%)
Ken Fisher 60,164 sh (-47.89%)
» More
» Details

Insider Trades

Latest Guru Trades with PETS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers    NAICS: 541940    SIC: 5912
Compare: » details
Traded in other countries:PQM.Germany,
PetMed Express Inc is a nationwide pet pharmacy. The Company markets prescription and non-prescription pet medications and other health products for dogs, cats, and horses direct to the consumer.

PetMed Express Inc was incorporated in the state of Florida in January 1996. The Company is a nationwide pet pharmacy. It markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. It markets its products through national television, online, and direct mail/print advertising campaigns, which aim to increase the recognition of the "1-800-PetMeds" brand name and "PetMeds". It offers a selection of products for dogs and cats. Its current product line contains approximately 3,000 SKUs of the popular pet medications, health products, and supplies. These products include a majority of the brands of medication, such as Frontline Plus, K9 Advantix II, Advantage II, Heartgard Plus, Sentinel, Revolution, and Rimadyl. The Company offers its products through three main sales channels: Internet through its website, telephone contact center through its toll-free number, and direct mail/print through 1-800-PetMeds catalogs, brochures, and postcards. It have designed its website and catalogs to provide a convenient, cost-effective, and informative shopping experience that encourages consumers to purchase products important for a pet's health and quality of life. Its customers are located throughout the United States, with approximately 50% of customers residing in California, Florida, New York, Texas, Pennsylvania, Virginia, North Carolina, and New Jersey. Its primary focus has been on retail customers. Its competitors consist of veterinarians, and online and traditional retailers. Its trademarks include PetMed Express and Design, 1888PetMeds and Design, 1-800-PetMeds and Design, 1-800-PetMeds, and PetMeds. The Company is subject to regulation by the State of Florida and is licensed as a community pharmacy by the Florida Board of Pharmacy.

Ratios

vs
industry
vs
history
PE Ratio 18.83
PETS's PE Ratio is ranked higher than
58% of the 424 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 21.03 vs. PETS: 18.83 )
Ranked among companies with meaningful PE Ratio only.
PETS' s PE Ratio Range Over the Past 10 Years
Min: 11.34  Med: 16.6 Max: 35.54
Current: 18.83
11.34
35.54
Forward PE Ratio 18.90
PETS's Forward PE Ratio is ranked lower than
60% of the 96 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.73 vs. PETS: 18.90 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 18.83
PETS's PE Ratio without NRI is ranked higher than
57% of the 332 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.66 vs. PETS: 18.83 )
Ranked among companies with meaningful PE Ratio without NRI only.
PETS' s PE Ratio without NRI Range Over the Past 10 Years
Min: 11.34  Med: 16.6 Max: 35.54
Current: 18.83
11.34
35.54
Price-to-Owner-Earnings 18.77
PETS's Price-to-Owner-Earnings is ranked higher than
52% of the 210 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 19.59 vs. PETS: 18.77 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
PETS' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.6  Med: 18.79 Max: 49.49
Current: 18.77
8.6
49.49
PB Ratio 4.63
PETS's PB Ratio is ranked lower than
82% of the 433 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.91 vs. PETS: 4.63 )
Ranked among companies with meaningful PB Ratio only.
PETS' s PB Ratio Range Over the Past 10 Years
Min: 2.33  Med: 4.33 Max: 11.32
Current: 4.63
2.33
11.32
PS Ratio 1.69
PETS's PS Ratio is ranked lower than
87% of the 394 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.50 vs. PETS: 1.69 )
Ranked among companies with meaningful PS Ratio only.
PETS' s PS Ratio Range Over the Past 10 Years
Min: 0.84  Med: 1.54 Max: 3.11
Current: 1.69
0.84
3.11
Price-to-Free-Cash-Flow 2517.50
PETS's Price-to-Free-Cash-Flow is ranked lower than
100% of the 200 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 21.37 vs. PETS: 2517.50 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PETS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.89  Med: 18.55 Max: 2883.75
Current: 2517.5
7.89
2883.75
Price-to-Operating-Cash-Flow 13.65
PETS's Price-to-Operating-Cash-Flow is ranked lower than
65% of the 261 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 11.24 vs. PETS: 13.65 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PETS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.7  Med: 16.05 Max: 41.42
Current: 13.65
7.7
41.42
EV-to-EBIT 10.63
PETS's EV-to-EBIT is ranked higher than
77% of the 436 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 15.27 vs. PETS: 10.63 )
Ranked among companies with meaningful EV-to-EBIT only.
PETS' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.7  Med: 9.2 Max: 22.4
Current: 10.63
4.7
22.4
EV-to-EBITDA 10.29
PETS's EV-to-EBITDA is ranked higher than
57% of the 447 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 11.34 vs. PETS: 10.29 )
Ranked among companies with meaningful EV-to-EBITDA only.
PETS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.5  Med: 8.95 Max: 21.8
Current: 10.29
4.5
21.8
PEG Ratio 11.06
PETS's PEG Ratio is ranked lower than
86% of the 166 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.13 vs. PETS: 11.06 )
Ranked among companies with meaningful PEG Ratio only.
PETS' s PEG Ratio Range Over the Past 10 Years
Min: 0.33  Med: 0.7 Max: 94
Current: 11.06
0.33
94
Shiller PE Ratio 20.32
PETS's Shiller PE Ratio is ranked higher than
61% of the 79 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 22.66 vs. PETS: 20.32 )
Ranked among companies with meaningful Shiller PE Ratio only.
PETS' s Shiller PE Ratio Range Over the Past 10 Years
Min: 13.11  Med: 18.12 Max: 50.21
Current: 20.32
13.11
50.21
Current Ratio 8.53
PETS's Current Ratio is ranked higher than
98% of the 324 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.20 vs. PETS: 8.53 )
Ranked among companies with meaningful Current Ratio only.
PETS' s Current Ratio Range Over the Past 10 Years
Min: 0.29  Med: 7.14 Max: 17.46
Current: 8.53
0.29
17.46
Quick Ratio 6.65
PETS's Quick Ratio is ranked higher than
98% of the 324 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.70 vs. PETS: 6.65 )
Ranked among companies with meaningful Quick Ratio only.
PETS' s Quick Ratio Range Over the Past 10 Years
Min: 0.11  Med: 4.66 Max: 14.61
Current: 6.65
0.11
14.61
Days Inventory 44.32
PETS's Days Inventory is ranked lower than
59% of the 328 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 38.50 vs. PETS: 44.32 )
Ranked among companies with meaningful Days Inventory only.
PETS' s Days Inventory Range Over the Past 10 Years
Min: 44.32  Med: 63.9 Max: 78.88
Current: 44.32
44.32
78.88
Days Sales Outstanding 2.33
PETS's Days Sales Outstanding is ranked higher than
86% of the 249 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 13.60 vs. PETS: 2.33 )
Ranked among companies with meaningful Days Sales Outstanding only.
PETS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.31  Med: 3.06 Max: 4.79
Current: 2.33
2.31
4.79
Days Payable 11.80
PETS's Days Payable is ranked lower than
93% of the 253 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 47.14 vs. PETS: 11.80 )
Ranked among companies with meaningful Days Payable only.
PETS' s Days Payable Range Over the Past 10 Years
Min: 11.53  Med: 13.73 Max: 21.9
Current: 11.8
11.53
21.9

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.77
PETS's Dividend Yield % is ranked higher than
82% of the 466 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.88 vs. PETS: 3.77 )
Ranked among companies with meaningful Dividend Yield % only.
PETS' s Dividend Yield % Range Over the Past 10 Years
Min: 0.51  Med: 4.13 Max: 5.85
Current: 3.77
0.51
5.85
Dividend Payout Ratio 0.70
PETS's Dividend Payout Ratio is ranked higher than
50% of the 290 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.77 vs. PETS: 0.70 )
Ranked among companies with meaningful Dividend Payout Ratio only.
PETS' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.26  Med: 0.7 Max: 0.78
Current: 0.7
0.26
0.78
3-Year Dividend Growth Rate 6.30
PETS's 3-Year Dividend Growth Rate is ranked lower than
52% of the 178 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.90 vs. PETS: 6.30 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
PETS' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 26
Current: 6.3
0
26
Forward Dividend Yield % 3.79
PETS's Forward Dividend Yield % is ranked higher than
80% of the 440 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.11 vs. PETS: 3.79 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 5.75
PETS's 5-Year Yield-on-Cost % is ranked higher than
79% of the 502 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.86 vs. PETS: 5.75 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
PETS' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.78  Med: 6.3 Max: 8.92
Current: 5.75
0.78
8.92
3-Year Average Share Buyback Ratio -0.60
PETS's 3-Year Average Share Buyback Ratio is ranked higher than
52% of the 195 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: -0.60 vs. PETS: -0.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PETS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -45.6  Med: -0.15 Max: 4.5
Current: -0.6
-45.6
4.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 10.44
PETS's Price-to-Net-Cash is ranked higher than
57% of the 21 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 11.79 vs. PETS: 10.44 )
Ranked among companies with meaningful Price-to-Net-Cash only.
PETS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.77  Med: 8.7 Max: 34.59
Current: 10.44
3.77
34.59
Price-to-Net-Current-Asset-Value 6.94
PETS's Price-to-Net-Current-Asset-Value is ranked lower than
56% of the 140 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.39 vs. PETS: 6.94 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PETS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.56  Med: 5.74 Max: 40
Current: 6.94
2.56
40
Price-to-Tangible-Book 4.67
PETS's Price-to-Tangible-Book is ranked lower than
75% of the 374 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.25 vs. PETS: 4.67 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PETS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.37  Med: 4.95 Max: 243.33
Current: 4.67
2.37
243.33
Price-to-Intrinsic-Value-Projected-FCF 1.81
PETS's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
60% of the 272 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.52 vs. PETS: 1.81 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
PETS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.54  Med: 1.3 Max: 24.02
Current: 1.81
0.54
24.02
Price-to-Median-PS-Value 1.10
PETS's Price-to-Median-PS-Value is ranked higher than
53% of the 381 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.14 vs. PETS: 1.10 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PETS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.3  Med: 0.99 Max: 2.02
Current: 1.1
0.3
2.02
Price-to-Peter-Lynch-Fair-Value 3.26
PETS's Price-to-Peter-Lynch-Fair-Value is ranked lower than
77% of the 149 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.69 vs. PETS: 3.26 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
PETS' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.55  Med: 0.79 Max: 3.74
Current: 3.26
0.55
3.74
Price-to-Graham-Number 1.98
PETS's Price-to-Graham-Number is ranked lower than
65% of the 308 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.59 vs. PETS: 1.98 )
Ranked among companies with meaningful Price-to-Graham-Number only.
PETS' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.09  Med: 1.96 Max: 5.88
Current: 1.98
1.09
5.88
Earnings Yield (Greenblatt) % 9.39
PETS's Earnings Yield (Greenblatt) % is ranked higher than
79% of the 475 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.00 vs. PETS: 9.39 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PETS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.5  Med: 10.9 Max: 21.2
Current: 9.39
4.5
21.2
Forward Rate of Return (Yacktman) % 9.70
PETS's Forward Rate of Return (Yacktman) % is ranked higher than
59% of the 235 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 8.05 vs. PETS: 9.70 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
PETS' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0.9  Med: 15.15 Max: 65.7
Current: 9.7
0.9
65.7

More Statistics

Revenue (TTM) (Mil) $241.5
EPS (TTM) $ 1.07
Beta0.33
Short Percentage of Float19.65%
52-Week Range $17.24 - 23.78
Shares Outstanding (Mil)20.53

Analyst Estimate

Mar17 Mar18 Mar19
Revenue (Mil $)
EPS ($) 1.02 1.06 1.06
EPS without NRI ($) 1.02 1.06 1.06
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for PETS

Headlines

Articles On GuruFocus.com
Own These Four Dividend Stocks Instead of a Condo Nov 04 2015 
10 High-Yielding Small Caps For A Portfolio Return Boost Apr 23 2015 
Bob Olstein Says Forget Amazon, Buy PetSmart, Teradata Jun 13 2014 
PetMed Express Inc. Is Trying Harder to Push Sales Apr 21 2014 
4 Cash Gushing, Undervalued Small Cap Stocks With Zero Debt Apr 08 2014 
4 Biggest Dividend Challengers with Low Debt and Nice Initial Yields Aug 28 2013 
12 Dividend Stocks Sending More Cash to Shareholders Aug 05 2013 
My 3 Favorite Healthcare Dividend Stocks with Highest Float Short Ratio Jun 03 2013 
PetMed Express - Debt-Free with Attractive Dividend Yield Nov 26 2012 
Horatio Gulash: Analyzing Advertising Expense Jun 11 2012 

More From Other Websites
PetMed Express' New Order Sales Disappoint, Competition Rife Mar 24 2017
AmsterDog Rescue to Ring The Nasdaq Stock Market Opening Bell in Celebration of National Puppy Day Mar 22 2017
PetMed Express, Inc. : PETS-US: Dividend Analysis : February 06th, 2017 (record date) : By the... Mar 21 2017
PETMED EXPRESS INC Files SEC form 8-K, Other Events Feb 06 2017
PETMED EXPRESS INC Financials Feb 03 2017
PETMED EXPRESS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal... Feb 03 2017
PetMed (PETS) Lags Q3 Earnings Estimates, Tops Revenues Jan 26 2017
PETMED EXPRESS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 25 2017
ETFs with exposure to PetMed Express, Inc. : January 25, 2017 Jan 25 2017
PetMed Express, Inc. :PETS-US: Earnings Analysis: Q3, 2017 By the Numbers : January 24, 2017 Jan 24 2017
PetMed Express, Inc. – Value Analysis (NASDAQ:PETS) : January 23, 2017 Jan 23 2017
Edited Transcript of PETS earnings conference call or presentation 23-Jan-17 1:30pm GMT Jan 23 2017
PetMed tops 3Q revenue forecasts Jan 23 2017
PetMed tops 3Q revenue forecasts Jan 23 2017
PetMed Express D/B/A 1-800-PetMeds Announces Its Third Quarter Financial Results and Its $0.19 Per... Jan 23 2017
Q3 2016 Petmed Express Inc Earnings Release - 08:00 am ET Jan 23 2017
PetMed Express, Inc. breached its 50 day moving average in a Bearish Manner : PETS-US : January 20,... Jan 20 2017
PETMED EXPRESS INC Files SEC form 8-K, Other Events Jan 18 2017
PetMed Express D/B/A 1-800-PETMEDS to Announce Its Third Quarter Financial Results on January 23,... Jan 17 2017
PetMed Express, Inc. : PETS-US: Dividend Analysis : November 07th, 2016 (record date) : By the... Jan 05 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)